Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 2 recruiting now small index

Primary Refractory Acute Myeloid Leukemia clinical trials

2 of 2 indexed Primary Refractory Acute Myeloid Leukemia trials are currently recruiting.

Corpus placement: #7,188 of 28,707 conditions by registered trial count.

2 US clinical trials · 2 currently recruiting · #7,188 of 28,707 conditions by registered trial count

Primary Refractory Acute Myeloid Leukemia: 2 US clinical trials tracked, 2 recruiting.

Primary Refractory Acute Myeloid Leukemia is the subject of 2 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. The most active sponsor is Massachusetts General Hospital, running 2 of these trials.

Enrollment posture brief

Registry condition primary-refractory-acute-myeloid-leukemia

OPEN 2 | RECR 100% | LATE 0 | EARLY 0 | RANK #7188 | SPON 2

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Primary Refractory Acute (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Primary Refractory Acute Myeloid Leukemia

Primary Refractory Acute Myeloid Leukemia lists 2 open slots (100% of 2 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Primary Refractory Acute Myeloid Leukemia on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Primary Refractory Acute Myeloid Leukemia is recruiting above its size-band peers.

    2 of 2 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase Distribution

Phase data not available

Top Sponsors

Named interventions

Most-linked intervention names on Primary Refractory Acute Myeloid Leukemia records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

Primary Palliative Care Behavioral
1 trials
Specialty Palliative Care Behavioral
1 trials
Vital Wellness Behavioral
1 trials
DREAMLAND Behavioral
1 trials

US sites by state

Facility locations filed on Primary Refractory Acute Myeloid Leukemia trials. A trial with sites in several states counts in each.

Washington 2 trials
North Carolina 2 trials
Massachusetts 2 trials
Wisconsin 1 trials
Pennsylvania 1 trials
Oregon 1 trials
Ohio 1 trials
New York 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Primary Refractory Acute Myeloid Leukemia page

2 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 2 Primary Refractory Acute Myeloid Leukemia trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • Massachusetts General Hospital sponsors the most Primary Refractory Acute Myeloid Leukemia trials on record, review their full trial history before evaluating a specific study. See Massachusetts General Hospital's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Primary Refractory Acute Myeloid Leukemia condition card totals 2 registered trials; most-linked intervention Primary Palliative Care; top US site state Washington. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.